Chief of Staff at Arcellx

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Cell Therapy, ImmunotherapyIndustries

Requirements

Bachelor’s degree required; advanced degree in the life sciences / healthcare (MBA or PhD) strongly preferred
6+ years of experience in healthcare/biotech/pharma consulting, strategy, banking, or investor relations. With an advanced degree, 4+ years are ideal
Proven ability to lead cross-functional initiatives and influence senior leaders
Exceptional written, verbal, and visual communication skills
Highly organized, with the ability to manage multiple complex projects simultaneously
Comfortable operating in a constantly evolving biotech environment
High integrity, sound judgment, and discretion handling sensitive information

Responsibilities

Partner with the CEO and executive team to define and operationalize company strategy and goals
Lead or support cross-functional strategic initiatives that require executive sponsorship and coordination
Champion the company’s values and help cultivate a high-performance, collaborative culture
Partner with functional leaders to align efforts and track progress against strategic milestones
Assist in managing the CEO’s priorities, schedule, and briefing materials to maximize impact and focus
Draft communications, presentations, and strategic updates for internal and external audiences
Support Board meeting preparation, including quarterly decks, talking points, and data synthesis

Skills

Executive Partnership

Strategic Prioritization

Leadership Communication

Operational Alignment

Board Management

Cross-Functional Collaboration

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters

2014Year Founded

$194.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.

Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.

Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.

The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.

ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.

Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.

Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI

Try Jobo Free